Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

IsraCann Biosciences, Inc. Cannabis Stock

IsaCann Biosciences, Inc.

IsraCann Biosciences, Inc. (ISCNF) is Israel’s first pure-play cannabis company. They grow outside Tel Aviv and are trying to produce low cost cannabis for exportation into Europe. ISCNF cannabis stock is listed on the OTC markets and are headquartered in Vancouver, Canada.

Is ISCNF a strong BUY and HOLD?

IsraCann Biosciences Fundamental Analysis

Profile

HQ: Vancouver, BC, Canada
Founded: 2010
Facilities: Tel Aviv, Israel
Symbol: ISCNF (OTC), IPOT (CSE)

Focus: Strong

IsraCann is an Israeli firm focused on cultivation. They’re targeting outdoor grows to utilize the ground and sun in Israel to attempt to make low cost cannabis for export into Europe.

They are targeting production costs of only $0.40 per gram (compared to an average of $1.50 per gram in Canada). 

Size: Weak

Market Cap: US $24.27 mil
Enterprise Value: US $21.75 mil
# of employees: 3

Markets: Strong

Primary: Israel
Secondary: Europe starting with Germany
Majority Subsidiaries:   Cannisra crops Ltd, Isracann Holdings Inc, The Cranium
 

Operations: Neutral

Cultivation:
Current production: They have a JV  with 55,000 sq ft
Future capacity:  The JV can grow to 160,000 sq ft in greenhouses with lots of outdoor land available to them. Their own facility will be 230,000 sq ft and have capacity of 23,500 kg per year.

Israel was the 3rd country to develop an export framework for cannabis (behind Canada and the Netherlands). They will use this to their advantage and supply Europe with their low cost cannabis.

Israel has 46,000 medical patients with 90,000 anticipated by year’s end. 

Distribution:
Direct sales: Yes
Store networks: None

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

2020 Revenue (ttm): $310,346
Outstanding shares (diluted): 135 mil
Return on Equity: -116%

Management: Weak

President, CEO, Director: Darryl Jones
CFO: Yana Popova
COO: Matt Chatterton

Management experience includes investment advising, project management, and accounting.

Branding: Neutral

They will rely heavily on the “made in Israel” brand with a focus on quality. Both cannabis for export as well as CBD products will be explored. Low cost, lots of sun, and good soil are all benefits of growing in Israel.

Valuation: Neutral

Current share price: US $0.1748
Price to Sales: 8.83 (Tobacco industry = 5)
52 week low/high: US $0.0908- $0.549
EV/Revenue: 54.02
Price/book: 1.21

Financing: Weak

After Q3 2020 (August 31st, 2020) they had $3 million of working capital. They raised about $150k through warrants and options. The company has around $1 million in debt.

ISCNF Technical Analysis

Should I buy IsraCann Biosciences?

Follow Stephen Goldman as he evaluates IsraCann Biosciences (ISCNF) using different moving averages, the Aroon Up/Down, and the stochastic RSI.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

/
Day Range -
52 Week Range -
Market Cap
Shares Traded
Volume

Bottom Line: Is IsraCann Biosciences Cannabis Stock a Buy?

Recommendation: Neutral (for now)

IsraCann Biosciences, Inc. is a cannabis cultivator in Israel. They are striving to become a low cost cultivator, which will give them an advantage in exporting their products to Germany and eventually all of the EU.

IsraCann has been slightly delayed in planting their first crop and blame covid-19 as well as licensing. The good news is that the Israeli government has approved rules for export of cannabis. This export will occur at a fixed price of CAD $5.50 per gram. If they are indeed able to produce cannabis at $0.40 per gram there would be fantastic profit margins in supplying the EU with smokable cannabis.

Locally the Israeli market is growing too. With an estimated 200,000 patients consuming an estimated 85 tonnes per year, there should be plenty of demand locally. Although they have no revenue yet from cannabis related businesses, they do have promise. They just need to get that first crop planted.

The company reported losses of $838,792 during the three months ending August 31st, 2020. This is compared to new losses of $894,848 in 2019. They have around $3 million in working capital so they can fund most of 2021 now. Without significant revenue after that from cultivating they will need to raise funds.

We generally like this company, although the management team is slightly inexperienced. If they can have a few successful harvests and export to Germany, there will be revenue to drive stock prices higher. This is at least 5-6 months away however. For the short term, this is rated Neutral but watch it long term for this to switch to Strong.

If you are looking for more productive cannabis companies, check out our Featured Companies Page for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change
Algorithmic Stock Trading Hemp Stocks

Rhode Island Senate Approves Recreational Marijuana

In historic vote, Senate passes legislation to legalize, tax, and regulate cannabis in Rhode Island. Proposal aims to create a competitive, inclusive, and equitable regulatory structure Rhode Island Senate Approves Recreational Marijuana -- STATE HOUSE, Providence –...

Nextleaf Awarded US Patent, Engages CannDelta for Psychedelics License

Nextleaf Awarded US Patent, Engages CannDelta for Psychedelics License -- Vancouver, British Columbia--(Newsfile Corp. - June 23, 2021) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf", "OILS", or the "Company"), the world's most innovative cannabis...

Maple Leaf Green World Inc. Secures a LOI to Purchase CBD Fusions LLC

Maple Leaf Green World Inc. Secures a LOI to Purchase CBD Fusions LLC -- CALGARY, Alberta, June 22, 2021 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“Maple Leaf” or the “Company”), (CSE: MGW) and (OTCQB: MGWFF), is pleased to announce that it has secured a letter...

Medical Cannabis Market Growth Sturdy at 23.9% CAGR

The Medical Cannabis Market Growth impelled by the increasing number of approvals for medical cannabis products, rising acceptance for the medicinal use of cannabis in developing countries, growing research on the medicinal use of cannabis; while flowers segment to...

Canopy Growth Completes Acquisition of Supreme

Acquisition solidifies Canopy Growth's leadership position in the Canadian recreational market Canopy Growth Completes Acquisition of Supreme -- SMITHS FALLS, ON, June 23, 2021 /PRNewswire/ - Canopy Growth Corporation ("Canopy") (TSX: WEED) (NASDAQ: CGC) and The...

Governor Lamont Signs Bill Legalizing Adult-Use Cannabis in Connecticut

Governor Lamont Signs Bill Legalizing and Safely Regulating Adult-Use Cannabis in Connecticut --(HARTFORD, CT) – Governor Ned Lamont this afternoon signed into law legislation that legalizes and safely regulates the adult-use of cannabis in Connecticut. The...